We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
Read MoreHide Full Article
Key Takeaways
OPKO Health is benefiting from NGENLA, Rayaldee and expanding international pharmaceutical opportunities.
Partnerships with Regeneron, Merck and BARDA help advance multiple programs while sharing development costs.
OPKO Health raised $125 million through senior secured notes backed by its mazdutide royalty interests.
OPKO Health, Inc.’s (OPK - Free Report) shares have jumped 32.5% year to date, showing impressive momentum. It has significantly outperformed the industry’s 6.9% decline and the S&P 500’s 11.5% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company is likely to maintain the wealth gain for its existing investors. However, adding this stock to one’s portfolio is not advised right now.
Miami, FL-based OPKO Health is a multinational biopharmaceutical and diagnostics company with operations across the United States, Ireland, Chile, Spain, Israel and Mexico. The company operates through two core businesses — diagnostics and pharmaceuticals — supported by a growing portfolio of strategic partnerships. Its portfolio includes the BioReference Health diagnostics business, pharmaceutical products such as RAYALDEE and NGENLA and a pipeline of investigational therapies spanning oncology, immunology, metabolic diseases and other areas.
Image Source: Zacks Investment Research
Key Catalysts for OPK’s Growth
OPKO Health is building a diversified pharmaceutical business supported by Rayaldee, NGENLA and its international operations. NGENLA, commercialized by Pfizer, is marketed in more than 50 markets and continues to benefit from the shift toward once-weekly growth hormone therapy. The amended Nicoya agreement also expands the potential of Rayaldee in Greater China, with OPKO retaining a 15% equity interest and eligibility for up to $115 million in development, regulatory and sales-based milestones. These commercial opportunities provide multiple avenues for recurring pharmaceutical growth.
OPKO is progressing with a broad clinical-candidate pipeline spanning oncology, immunology, metabolic disorders and infectious diseases. ModeX has five programs in clinical development, including the MDX3001 in vivo CAR-T program advancing toward first-in-human studies targeted for late 2026 or early 2027. Other potential catalysts include clinical progress for MDX2001, MDX2003 and MDX2004, the Merck (MRK - Free Report) -funded MDX2201 EBV vaccine and the BARDA-supported MDX2301 program. Beyond ModeX, OPK-88006 is being evaluated as a once-weekly GLP-1/glucagon agonist for MASH, while OPK8801001 is advancing as a potential once-weekly treatment for acromegaly.
Partnerships with Regeneron, Merck and BARDA enable OPKO to advance multiple programs while sharing development costs. The Regeneron collaboration could generate more than $1 billion in milestones and tiered royalties of up to the low double digits.
The latest financing announcement provides another potential catalyst. OPKO issued an additional $125 million of senior secured notes to HealthCare Royalty, secured by its mazdutide royalty interests under its licensing agreement with Eli Lilly. The non-dilutive financing provides additional capital while allowing OPKO to retain meaningful long-term participation in the mazdutide royalty stream.
Factors That May Offset OPK’s Gains
OPKO Health’s growth prospects depend on successful execution across its clinical pipeline. Delays in enrollment, clinical milestones or regulatory decisions for ModeX programs, OPK-88006, OPK8801001 and its in vivo CAR-T program could postpone commercialization opportunities. Advancing multiple programs across therapeutic areas requires significant R&D investment. While partnerships with Regeneron, Merck and BARDA help offset some costs, OPKO remains exposed to expenses from programs that may take years to generate returns.
BioReference’s growth depends partly on broader adoption of 4Kscore and reimbursement expansion. Delays in Medicare decisions or slower development of new revenue channels could limit the diagnostics segment’s contribution.
Several growth opportunities rely on partners for commercialization and market access. NGENLA depends on Pfizer’s execution, while mazdutide royalty growth depends on continued product performance in China. Changes in partner priorities or product adoption could affect OPKO’s potential returns.
Taking a Look at OPK’s Estimates
In the past 30 days, the Zacks Consensus Estimate for its loss per share has remained unchanged at 23 cents.
Revenues are projected to decline 6.2% to $569 million in 2026 and grow 2.5% to $583.2 million in 2027.
Veracyte reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.
View the Zacks #1 Rank List
Image: Shutterstock
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
Key Takeaways
OPKO Health, Inc.’s (OPK - Free Report) shares have jumped 32.5% year to date, showing impressive momentum. It has significantly outperformed the industry’s 6.9% decline and the S&P 500’s 11.5% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company is likely to maintain the wealth gain for its existing investors. However, adding this stock to one’s portfolio is not advised right now.
Miami, FL-based OPKO Health is a multinational biopharmaceutical and diagnostics company with operations across the United States, Ireland, Chile, Spain, Israel and Mexico. The company operates through two core businesses — diagnostics and pharmaceuticals — supported by a growing portfolio of strategic partnerships. Its portfolio includes the BioReference Health diagnostics business, pharmaceutical products such as RAYALDEE and NGENLA and a pipeline of investigational therapies spanning oncology, immunology, metabolic diseases and other areas.
Image Source: Zacks Investment Research
Key Catalysts for OPK’s Growth
OPKO Health is building a diversified pharmaceutical business supported by Rayaldee, NGENLA and its international operations. NGENLA, commercialized by Pfizer, is marketed in more than 50 markets and continues to benefit from the shift toward once-weekly growth hormone therapy. The amended Nicoya agreement also expands the potential of Rayaldee in Greater China, with OPKO retaining a 15% equity interest and eligibility for up to $115 million in development, regulatory and sales-based milestones. These commercial opportunities provide multiple avenues for recurring pharmaceutical growth.
OPKO is progressing with a broad clinical-candidate pipeline spanning oncology, immunology, metabolic disorders and infectious diseases. ModeX has five programs in clinical development, including the MDX3001 in vivo CAR-T program advancing toward first-in-human studies targeted for late 2026 or early 2027. Other potential catalysts include clinical progress for MDX2001, MDX2003 and MDX2004, the Merck (MRK - Free Report) -funded MDX2201 EBV vaccine and the BARDA-supported MDX2301 program. Beyond ModeX, OPK-88006 is being evaluated as a once-weekly GLP-1/glucagon agonist for MASH, while OPK8801001 is advancing as a potential once-weekly treatment for acromegaly.
Partnerships with Regeneron, Merck and BARDA enable OPKO to advance multiple programs while sharing development costs. The Regeneron collaboration could generate more than $1 billion in milestones and tiered royalties of up to the low double digits.
The latest financing announcement provides another potential catalyst. OPKO issued an additional $125 million of senior secured notes to HealthCare Royalty, secured by its mazdutide royalty interests under its licensing agreement with Eli Lilly. The non-dilutive financing provides additional capital while allowing OPKO to retain meaningful long-term participation in the mazdutide royalty stream.
Factors That May Offset OPK’s Gains
OPKO Health’s growth prospects depend on successful execution across its clinical pipeline. Delays in enrollment, clinical milestones or regulatory decisions for ModeX programs, OPK-88006, OPK8801001 and its in vivo CAR-T program could postpone commercialization opportunities. Advancing multiple programs across therapeutic areas requires significant R&D investment. While partnerships with Regeneron, Merck and BARDA help offset some costs, OPKO remains exposed to expenses from programs that may take years to generate returns.
BioReference’s growth depends partly on broader adoption of 4Kscore and reimbursement expansion. Delays in Medicare decisions or slower development of new revenue channels could limit the diagnostics segment’s contribution.
Several growth opportunities rely on partners for commercialization and market access. NGENLA depends on Pfizer’s execution, while mazdutide royalty growth depends on continued product performance in China. Changes in partner priorities or product adoption could affect OPKO’s potential returns.
Taking a Look at OPK’s Estimates
In the past 30 days, the Zacks Consensus Estimate for its loss per share has remained unchanged at 23 cents.
Revenues are projected to decline 6.2% to $569 million in 2026 and grow 2.5% to $583.2 million in 2027.
Key Picks
A couple of top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) and Inspire Medical Systems (INSP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.